Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
16. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
View |
17. |
ECCT/22/09/03 | SINGLE DOSE VERSUS EXTENDED DO EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU COUNTY,KENYA: A RANDOMIZED CONTROL TRIAL. |
Principal Investigator(s) 1. STEVEN ODHIAMBO JUMA Site(s) in Kenya JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL |
View |
18. |
ECCT/22/08/04 | Protocol H06_01TP A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S. flexneri, serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2) |
Principal Investigator(s) 1. Deborah Chepngeno Langat Langat Site(s) in Kenya KEMRI WRP CRC KERICHO |
View |
19. |
ECCT/22/04/02 | GO42144 A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS |
Principal Investigator(s) 1. Mansoor Noorali Saleh Site(s) in Kenya Aga Khan University, Nairobi |
View |
20. |
ECCT/22/03/03 | HVTN 140/HPTN 101 A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101 |
Principal Investigator(s) 1. Josphat kosgei Site(s) in Kenya KEMRI WRP, KERICHO |
View |